Novo Nordisk, Eli Lilly Report GLP-1 Signals of Slowed Biological Aging at ARDD

Novo Nordisk and Eli Lilly announced that their glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide, has shown signals of slowed biological aging in a study presented at the American Society for Radiation Oncology (ASTRO) 2022 conference. The study, conducted by the company ARDD (Aging Research and Development Denmark), found that semaglutide was associated with improved aging biomarkers and reduced cardiovascular risk in patients with type 2 diabetes. The study's results suggest that GLP-1 receptor agonists may have anti-aging effects, which could potentially be beneficial for people with type 2 diabetes and other age-related diseases.